Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease

Anita K. McElroy, Jessica R. Harmon, Timothy D. Flietstra, Shelley Campbell, Aneesh K. Mehta, Colleen S. Kraft, Marshall G. Lyon, Jay B. Varkey, Bruce S. Ribner, Christopher J Kratochvil, Peter Charles Iwen, Philip W. Smith, Rafi Ahmed, Stuart T. Nichol, Christina F. Spiropoulou

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background. Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. Methods. In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. Results. Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. Conclusions. Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.

Original languageEnglish (US)
Pages (from-to)460-467
Number of pages8
JournalClinical Infectious Diseases
Volume63
Issue number4
DOIs
StatePublished - Aug 15 2016

Fingerprint

Ebola Hemorrhagic Fever
Biomarkers
Viremia
Ebolavirus
Fatal Outcome
Chemokines
Interferons
Cytokines

Keywords

  • Biomarkers
  • Cytokines
  • EVD
  • Ebola
  • Immunity

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

McElroy, A. K., Harmon, J. R., Flietstra, T. D., Campbell, S., Mehta, A. K., Kraft, C. S., ... Spiropoulou, C. F. (2016). Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clinical Infectious Diseases, 63(4), 460-467. https://doi.org/10.1093/cid/ciw334

Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. / McElroy, Anita K.; Harmon, Jessica R.; Flietstra, Timothy D.; Campbell, Shelley; Mehta, Aneesh K.; Kraft, Colleen S.; Lyon, Marshall G.; Varkey, Jay B.; Ribner, Bruce S.; Kratochvil, Christopher J; Iwen, Peter Charles; Smith, Philip W.; Ahmed, Rafi; Nichol, Stuart T.; Spiropoulou, Christina F.

In: Clinical Infectious Diseases, Vol. 63, No. 4, 15.08.2016, p. 460-467.

Research output: Contribution to journalArticle

McElroy, AK, Harmon, JR, Flietstra, TD, Campbell, S, Mehta, AK, Kraft, CS, Lyon, MG, Varkey, JB, Ribner, BS, Kratochvil, CJ, Iwen, PC, Smith, PW, Ahmed, R, Nichol, ST & Spiropoulou, CF 2016, 'Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease', Clinical Infectious Diseases, vol. 63, no. 4, pp. 460-467. https://doi.org/10.1093/cid/ciw334
McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS et al. Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clinical Infectious Diseases. 2016 Aug 15;63(4):460-467. https://doi.org/10.1093/cid/ciw334
McElroy, Anita K. ; Harmon, Jessica R. ; Flietstra, Timothy D. ; Campbell, Shelley ; Mehta, Aneesh K. ; Kraft, Colleen S. ; Lyon, Marshall G. ; Varkey, Jay B. ; Ribner, Bruce S. ; Kratochvil, Christopher J ; Iwen, Peter Charles ; Smith, Philip W. ; Ahmed, Rafi ; Nichol, Stuart T. ; Spiropoulou, Christina F. / Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. In: Clinical Infectious Diseases. 2016 ; Vol. 63, No. 4. pp. 460-467.
@article{ec02e6797dd34873a908e26b4b5f5ad5,
title = "Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease",
abstract = "Background. Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. Methods. In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. Results. Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. Conclusions. Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.",
keywords = "Biomarkers, Cytokines, EVD, Ebola, Immunity",
author = "McElroy, {Anita K.} and Harmon, {Jessica R.} and Flietstra, {Timothy D.} and Shelley Campbell and Mehta, {Aneesh K.} and Kraft, {Colleen S.} and Lyon, {Marshall G.} and Varkey, {Jay B.} and Ribner, {Bruce S.} and Kratochvil, {Christopher J} and Iwen, {Peter Charles} and Smith, {Philip W.} and Rafi Ahmed and Nichol, {Stuart T.} and Spiropoulou, {Christina F.}",
year = "2016",
month = "8",
day = "15",
doi = "10.1093/cid/ciw334",
language = "English (US)",
volume = "63",
pages = "460--467",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease

AU - McElroy, Anita K.

AU - Harmon, Jessica R.

AU - Flietstra, Timothy D.

AU - Campbell, Shelley

AU - Mehta, Aneesh K.

AU - Kraft, Colleen S.

AU - Lyon, Marshall G.

AU - Varkey, Jay B.

AU - Ribner, Bruce S.

AU - Kratochvil, Christopher J

AU - Iwen, Peter Charles

AU - Smith, Philip W.

AU - Ahmed, Rafi

AU - Nichol, Stuart T.

AU - Spiropoulou, Christina F.

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Background. Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. Methods. In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. Results. Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. Conclusions. Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.

AB - Background. Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. Methods. In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. Results. Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. Conclusions. Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.

KW - Biomarkers

KW - Cytokines

KW - EVD

KW - Ebola

KW - Immunity

UR - http://www.scopus.com/inward/record.url?scp=84982161860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982161860&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw334

DO - 10.1093/cid/ciw334

M3 - Article

C2 - 27353663

AN - SCOPUS:84982161860

VL - 63

SP - 460

EP - 467

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -